bioAffinity and AvMEDICAL bring CyPath Lung test to VA conference
The companies presented their new federal distribution partnership for the noninvasive lung cancer test to VA leaders and physicians in Arlington, Virginia.
bioAffinity Technologies, Inc. and its federal healthcare distribution partner AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, jointly showcased the CyPath® Lung test to VA leadership and healthcare providers during the week of September 30, 2026, as disclosed in an 8-K filed that day. The two companies gave more than 300 physicians, healthcare professionals and VA leaders their first joint look at CyPath Lung under the new distribution agreement, at the National Association of Veterans' Research and Education Foundations (NAVREF) Annual Conference in Arlington, Virginia.1
The arrangement is meant to widen government access to the test. The nationwide federal healthcare distribution agreement aims to expand government and agency access to CyPath Lung through AvMEDICAL's procurement channels, government contracting expertise and existing customer relationships.1 bioAffinity is also a member of NAVREF's Industry Partner Consortium, a platform meant to advance VA research.1
The company cited a significant disease burden among veterans: the VA reports that approximately 7,700 veterans are diagnosed with lung cancer each year.1
Separately, bioAffinity presented the test at the GO2 for Lung Cancer Centers of Excellence conference in San Diego during the same week. GO2 for Lung Cancer, a nonprofit that works with the VA, aims to raise awareness of lung cancer screening for veterans and broaden access through a network of more than 700 screening centers of excellence, while offering VA staff resources for screening implementation, patient education and research.1
On the test itself, the company said CyPath Lung uses flow cytometry and proprietary artificial intelligence to identify malignant cell populations in sputum samples, incorporating a fluorescent porphyrin taken up preferentially by cancer and cancer-related cells.1 In a cited clinical trial, the test showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value among high-risk patients with small indeterminate lung nodules under 20 millimeters.1 The test is marketed as a Laboratory Developed Test and is not intended as a sole diagnostic tool.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.